- Profitability: Beijing Tiantan’s first-quarter net income experienced a rise of 21% Year on Year (Y/Y), with a figure of 316.7 million yuan. This increased from 261.9 million yuan reported the same period last year – a significant leap in profitability.
- Revenue: Company’s revenue for the first quarter declined by 5.4% Y/Y, amounting to 1.22 billion yuan. While net income saw a surge, revenue dropped, indicating that the company has made operational efficiency improvements or cost reductions.
- Market Sentiment: The market reception of Beijing Tiantan’s Q1 results has been largely positive, with 14 buy ratings from analysts, and no hold or sell ratings at all. This signifies that market analysts are optimistic about the company’s future prospects.
- Comparative Analysis: These results are drawn from the company’s original disclosures. Thus, the financial performance and market sentiment for Beijing Tiantan are based on accurate, real-time data.
Beijing Tiantan Biological Products on Smartkarma
On Smartkarma, analyst Xinyao (Criss) Wang provides in-depth insights on Beijing Tiantan Biological Products. In the article “Tiantan (600161CH) To Acquire Weiguang (002880CH) – New King Rises in China’s Blood Products Industry,” Wang notes the potential impact of Weiguang’s restructuring on the blood products sector. With Weiguang’s shift in control to China National Biotec, potential competition and synergies with Tiantan, as a subsidiary of Sinopharm, are highlighted. The evolving landscape of the two companies in the SOE reform stage presents intriguing possibilities for investors.
In another report “China Healthcare Weekly (Jan.26) – Stocks Best Buying Point, Tragic PD-L1, Tiantan Biological Product,” Xinyao (Criss) Wang discusses investment opportunities amidst market fluctuations. While expressing pessimism about PD-L1 sales in China, Wang identifies Beijing Tiantan Biological Products as a sound defensive target, especially in challenging market conditions. With a projected market value and growth trajectory, Tiantan emerges as a stable investment option in the healthcare sector.
A look at Beijing Tiantan Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tiantan Biological Products Corporation Limited, a company that researches, develops, and commercializes biological products, appears to have a promising long-term outlook based on its Smartkarma Smart Scores. With strong scores in Growth, Resilience, and Momentum, the company seems well-positioned for future success.
Although Beijing Tiantan Biological Products received average scores in Value and Dividend, its high scores in Growth, Resilience, and Momentum indicate potential for significant future growth and a strong ability to withstand market challenges. Investors may find Beijing Tiantan Biological Products an appealing prospect for long-term investment based on its overall positive outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
